Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients

Mutsuko Ohnishi, Yoshinobu Kanda, Toshio Takeuchi, Sung Won Kim, Akiko Hori, Hironari Niiya, Aki Chizuka, Kunihisa Nakai, Takeshi Saito, Atsushi Makimoto, Ryuji Tanosaki, Takashi Watanabe, Yukio Kobayashi, Kensei Tobinai, Yoichi Takaue, Shin Mineishi

研究成果: Article

7 引用 (Scopus)

抄録

Background. Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stern cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%). Methods. In an attempt to identify a suitable procedure for the prevention and management of HBV re-activation, the administration of lamivudine over the course was tested in two patients. Results. Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high DNA polymerase activity despite prolonged administration of lamivudine. Conclusions. We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.

元の言語English
ページ(範囲)812-815
ページ数4
ジャーナルTransplantation
73
発行部数5
出版物ステータスPublished - 2002 3 15
外部発表Yes

Fingerprint

Lamivudine
Virus Diseases
Hematopoietic Stem Cells
Hepatitis B virus
Transplants
Cell Transplantation
Chronic Hepatitis B
Virus Activation
Organ Transplantation
Graft vs Host Disease
DNA-Directed DNA Polymerase
Immunosuppressive Agents
Transplant Recipients
Steroids
Therapeutics

ASJC Scopus subject areas

  • Transplantation
  • Immunology

これを引用

Ohnishi, M., Kanda, Y., Takeuchi, T., Won Kim, S., Hori, A., Niiya, H., ... Mineishi, S. (2002). Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. Transplantation, 73(5), 812-815.

Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. / Ohnishi, Mutsuko; Kanda, Yoshinobu; Takeuchi, Toshio; Won Kim, Sung; Hori, Akiko; Niiya, Hironari; Chizuka, Aki; Nakai, Kunihisa; Saito, Takeshi; Makimoto, Atsushi; Tanosaki, Ryuji; Watanabe, Takashi; Kobayashi, Yukio; Tobinai, Kensei; Takaue, Yoichi; Mineishi, Shin.

:: Transplantation, 巻 73, 番号 5, 15.03.2002, p. 812-815.

研究成果: Article

Ohnishi, M, Kanda, Y, Takeuchi, T, Won Kim, S, Hori, A, Niiya, H, Chizuka, A, Nakai, K, Saito, T, Makimoto, A, Tanosaki, R, Watanabe, T, Kobayashi, Y, Tobinai, K, Takaue, Y & Mineishi, S 2002, 'Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients', Transplantation, 巻. 73, 番号 5, pp. 812-815.
Ohnishi M, Kanda Y, Takeuchi T, Won Kim S, Hori A, Niiya H その他. Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. Transplantation. 2002 3 15;73(5):812-815.
Ohnishi, Mutsuko ; Kanda, Yoshinobu ; Takeuchi, Toshio ; Won Kim, Sung ; Hori, Akiko ; Niiya, Hironari ; Chizuka, Aki ; Nakai, Kunihisa ; Saito, Takeshi ; Makimoto, Atsushi ; Tanosaki, Ryuji ; Watanabe, Takashi ; Kobayashi, Yukio ; Tobinai, Kensei ; Takaue, Yoichi ; Mineishi, Shin. / Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. :: Transplantation. 2002 ; 巻 73, 番号 5. pp. 812-815.
@article{c7bd8800484445c4a789e911d87105f4,
title = "Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients",
abstract = "Background. Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stern cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12{\%}). Methods. In an attempt to identify a suitable procedure for the prevention and management of HBV re-activation, the administration of lamivudine over the course was tested in two patients. Results. Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high DNA polymerase activity despite prolonged administration of lamivudine. Conclusions. We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.",
author = "Mutsuko Ohnishi and Yoshinobu Kanda and Toshio Takeuchi and {Won Kim}, Sung and Akiko Hori and Hironari Niiya and Aki Chizuka and Kunihisa Nakai and Takeshi Saito and Atsushi Makimoto and Ryuji Tanosaki and Takashi Watanabe and Yukio Kobayashi and Kensei Tobinai and Yoichi Takaue and Shin Mineishi",
year = "2002",
month = "3",
day = "15",
language = "English",
volume = "73",
pages = "812--815",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients

AU - Ohnishi, Mutsuko

AU - Kanda, Yoshinobu

AU - Takeuchi, Toshio

AU - Won Kim, Sung

AU - Hori, Akiko

AU - Niiya, Hironari

AU - Chizuka, Aki

AU - Nakai, Kunihisa

AU - Saito, Takeshi

AU - Makimoto, Atsushi

AU - Tanosaki, Ryuji

AU - Watanabe, Takashi

AU - Kobayashi, Yukio

AU - Tobinai, Kensei

AU - Takaue, Yoichi

AU - Mineishi, Shin

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Background. Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stern cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%). Methods. In an attempt to identify a suitable procedure for the prevention and management of HBV re-activation, the administration of lamivudine over the course was tested in two patients. Results. Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high DNA polymerase activity despite prolonged administration of lamivudine. Conclusions. We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.

AB - Background. Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stern cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%). Methods. In an attempt to identify a suitable procedure for the prevention and management of HBV re-activation, the administration of lamivudine over the course was tested in two patients. Results. Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high DNA polymerase activity despite prolonged administration of lamivudine. Conclusions. We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.

UR - http://www.scopus.com/inward/record.url?scp=0037087581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037087581&partnerID=8YFLogxK

M3 - Article

C2 - 11907433

AN - SCOPUS:0037087581

VL - 73

SP - 812

EP - 815

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -